332369-80-9

Basic information

• Product Name: 1,2-Benzenedicarboxylic acid, 4-[2-(benzoylamino)phenoxy]-, dimethyl ester
• CAS NO: 332369-80-9
• Molecular Formula: C23H19NO6
• Molecular Weight: 405.407
• Mol File: 332369-80-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1,2-Benzenedicarboxylic acid, 4-[2-(benzoylamino)phenoxy]-, dimethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Benzenedicarboxylic acid, 4-[2-(benzoylamino)phenoxy]-, dimethyl ester(332369-80-9)
• EPA Substance Registry System: 1,2-Benzenedicarboxylic acid, 4-[2-(benzoylamino)phenoxy]-, dimethyl ester(332369-80-9)

Safety Data

• Hazardous Substances Data: 332369-80-9(Hazardous Substances Data)

Upstream product

• 332370-51-1 4-(2-nitrophenoxy)phthalic acid dimethyl ester 
• 1493-27-2 ortho-nitrofluorobenzene 
• 22479-95-4 dimethyl 4-hydroxyphthalate 
• 98-88-4 benzoyl chloride 
• 332370-57-7 4-(2-aminophenoxy)phthalic acid dimethyl ester 

Relevant articles and documents

Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases

The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

Aromatic compounds

Disclosed are compounds of formula I wherein A, R1, R2, R3, R4and R5are described in the specification, pharmaceutical formulations comprising these compounds, the use of these compounds are medicaments, the use of these medicaments in the treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (NIDDM or Type 2 diabetes), as well as methods for treating diabetes comprising administration of these compounds.